<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004702</url>
  </required_header>
  <id_info>
    <org_study_id>06272019</org_study_id>
    <nct_id>NCT04004702</nct_id>
  </id_info>
  <brief_title>Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)</brief_title>
  <acronym>LAPSE</acronym>
  <official_title>Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed National Military Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Alzheimer's disease (AD) are increasingly recognized to have seizures in
      addition to cognitive decline. Seizures may contribute to memory problems as well as other
      symptoms common in AD like agitation, depression, or apathy. These symptoms are collectively
      called neuro-psychiatric symptoms. Studies of magnetic resonance imaging (MRI) in patients
      with AD have suggested that injury to certain parts of the brain can cause these
      neuro-psychiatric symptoms. Based on this evidence, the investigators hypothesize that
      seizures can also cause neuro-psychiatric symptoms in patients with AD and may be related to
      the injury seen on MRI.

      The current study will follow participants for 1 year and will involve participants with AD
      who also have neuro-psychiatric symptoms. Participants will be examined with three brain wave
      studies to assess for seizure-like activity. Participants with seizure-like activity will all
      receive levetiracetam for 1 year. All participants will have their neuro-psychiatric
      symptoms, cognitive abilities, quality of life, and AD severity assessed throughout the year.
      The investigators plan to determine if levetiracetam changes the severity of the
      participants' neuro-psychiatric symptoms compared to their baseline as well as compared to
      participants without seizure-like activity. 65 participants will need to be recruited to test
      the study hypotheses. The study will take place at Walter Reed National Military Medical
      Center.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's Disease (AD) has long been known to carry an increased risk of seizure, with
      early estimates suggesting patients with AD have a 10-22% risk at least one unprovoked
      seizure and an 8- to 10-fold higher seizure rate over the general population. Retrospective
      data has suggested that the onset of both clinical seizure and abnormal discharge on
      electroencephalogram (EEG) may cluster around or even precede the onset of cognitive decline.
      With extended EEG and/or 1-hour magnetoencephalogram (MEG), up to 42% of patients with AD
      have evidence of subclinical seizure or epileptiform discharges, two-thirds of which were
      identified only during sleep. Recent evidence has also found a much higher incidence of
      dyscognitive seizure (47%) and other nonconvulsive semiologies (55%) than previously
      reported, including jamais vu, déjà vu, sensory phenomenon, speech arrest/aphasia, and
      amnestic spells.

      A particularly problematic aspect of dementia in general and AD in particular is
      neuropsychiatric symptoms. Neuropsychiatric symptoms increase with duration and severity of
      dementia, observed in as much as 60-90% of these patients. To some extent, neuropsychiatric
      symptoms may also be associated with focal dysfunction, particularly of the non-dominant
      fronto-temporal lobes. Seizure or transient epileptiform discharges, then, might explain some
      of the neuropsychiatric manifestations associated with AD, especially since the most common
      areas of discharge are the fronto-temporal lobes in AD. Neuropsychiatric symptoms and their
      causes are of particular concern in the management of patients with AD given the strain on
      patients and families and their high association with nursing home placement.

      This study will complete up to 3 serial EEGs on each participant, and all participants with
      epileptiform activity identified on EEG will be started on levetiracetam. All participants
      will be followed with serial neuro-psychiatric symptom, cognitive, severity, and
      quality-of-life metrics in order to analyze the effect of levetiracetam on these measures
      over 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants with clinical Alzheimer's disease and neuro-psychiatric symptoms will all be assessed with electroencephalogram, and all participants with epileptiform discharges will receive levetiracetam. Those without epileptiform discharges will be followed with serial inventories of symptom severity and functioning, but will not receive experimental treatment nor placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neuropsychiatric Inventory Score (NPI)</measure>
    <time_frame>Assessed at enrollment, week 7, week 15, week 27, and month 12</time_frame>
    <description>Neuropsychiatric Symptom Metric</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Dementia Rating Sum of Boxes (CDR-SOB)</measure>
    <time_frame>Assessed at enrollment, week 7, week 15, week 27, and month 12</time_frame>
    <description>Patient/Informant AD Severity Metric</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer's Disease Cooperative study - Clinical Global Impression of Change (ADCS-CGIC)</measure>
    <time_frame>Assessed at enrollment, week 7, week 15, week 27, and month 12</time_frame>
    <description>Clinician AD Severity Metric</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol 5-Dimension (EQ-5D)</measure>
    <time_frame>Assessed at enrollment, week 7, week 15, week 27, and month 12</time_frame>
    <description>Quality of Life Metric</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mini-Mental State Exam (MMSE)</measure>
    <time_frame>Assessed at enrollment, week 7, week 15, week 27, and month 12</time_frame>
    <description>Cognitive Ability Metric</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Levetiracetam 500mg twice a day</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the National Institute of Aging-Alzheimer's Association criteria for probable AD

          -  Twelve-item Neuropsychiatric Inventory with score 4 or greater

          -  MMSE &lt;26

          -  Stable doses current medications, including acetylcholinesterase inhibitors if
             applicable, for at least 4 weeks prior to trial entry

          -  Reliable caregiver willing and available to assist with medication administration,
             outcome measures

          -  MRI completed with no evidence of potential seizure focus as outlined in the exclusion
             criteria

        Exclusion Criteria:

          -  Imaging suggestive of potential seizure focus or alternative cause of dementia

          -  Previous Epilepsy diagnosis

          -  Use of anti-epileptic medication for any indication within previous three months

          -  History of head trauma with loss of consciousness more than 30 minutes

          -  Alcohol/Substance abuse within 5 years of dementia onset or previous 5 years

          -  History of Korsakoff's syndrome

          -  History of encephalitis/meningitis

          -  Female participant who is pregnant, lactating or planning pregnancy during trial

          -  Scheduled elective surgery or other procedures requiring general anesthesia during the
             trial

          -  Participant with life expectancy of less than 12 months

          -  Any cancer requiring current chemotherapy

          -  Known allergy or history of previous adverse reaction to levetiracetam

          -  Major depression or other significant behavioral disturbance preceding Alzheimer's
             Disease diagnosis

          -  Enrollment in another clinical treatment trial

          -  Laboratory evidence of an alternative cause of dementia or which might preclude
             treatment, including untreated vitamin B12 deficiency, untreated hypothyroidism,
             syphilis, positive human immunodeficiency virus testing, end-stage renal disease on
             dialysis, significant renal impairment (creatinine clearance &lt;75 ml/minute), or liver
             function tests &gt;2x upper limit of normal within the preceding three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy R Malone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed National Military Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy R Malone, MD</last_name>
    <phone>301-295-4771</phone>
    <email>timothy.r.malone5.mil@mail.mil</email>
  </overall_contact>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Timothy R Malone, MD</last_name>
      <phone>301-295-4771</phone>
      <email>timothy.r.malone5.mil@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Timothy R Malone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Swanberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph V Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adriana Martinez, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuamokumo Francois, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986 Sep;36(9):1226-30.</citation>
    <PMID>3092131</PMID>
  </reference>
  <reference>
    <citation>Romanelli MF, Morris JC, Ashkin K, Coben LA. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol. 1990 Aug;47(8):847-50.</citation>
    <PMID>2375689</PMID>
  </reference>
  <reference>
    <citation>Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 1995 Sep-Oct;6(5):258-63.</citation>
    <PMID>8528372</PMID>
  </reference>
  <reference>
    <citation>Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20(11):791-803. Review.</citation>
    <PMID>12964886</PMID>
  </reference>
  <reference>
    <citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006 May;47(5):867-72.</citation>
    <PMID>16686651</PMID>
  </reference>
  <reference>
    <citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009 Apr;66(4):435-40. doi: 10.1001/archneurol.2009.15. Epub 2009 Feb 9. Review.</citation>
    <PMID>19204149</PMID>
  </reference>
  <reference>
    <citation>Scarmeas N, Honig LS, Choi H, Cantero J, Brandt J, Blacker D, Albert M, Amatniek JC, Marder K, Bell K, Hauser WA, Stern Y. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol. 2009 Aug;66(8):992-7. doi: 10.1001/archneurol.2009.130.</citation>
    <PMID>19667221</PMID>
  </reference>
  <reference>
    <citation>Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, Moreau V, Charbonnier F, Didierjean O, Tardieu S, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet. 1995 Dec;4(12):2373-7.</citation>
    <PMID>8634712</PMID>
  </reference>
  <reference>
    <citation>Fox NC, Kennedy AM, Harvey RJ, Lantos PL, Roques PK, Collinge J, Hardy J, Hutton M, Stevens JM, Warrington EK, Rossor MN. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain. 1997 Mar;120 ( Pt 3):491-501.</citation>
    <PMID>9126060</PMID>
  </reference>
  <reference>
    <citation>Lopera F, Ardilla A, Martínez A, Madrigal L, Arango-Viana JC, Lemere CA, Arango-Lasprilla JC, Hincapíe L, Arcos-Burgos M, Ossa JE, Behrens IM, Norton J, Lendon C, Goate AM, Ruiz-Linares A, Rosselli M, Kosik KS. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997 Mar 12;277(10):793-9.</citation>
    <PMID>9052708</PMID>
  </reference>
  <reference>
    <citation>Axelman K, Basun H, Lannfelt L. Wide range of disease onset in a family with Alzheimer disease and a His163Tyr mutation in the presenilin-1 gene. Arch Neurol. 1998 May;55(5):698-702.</citation>
    <PMID>9605727</PMID>
  </reference>
  <reference>
    <citation>Janssen JC, Hall M, Fox NC, Harvey RJ, Beck J, Dickinson A, Campbell T, Collinge J, Lantos PL, Cipolotti L, Stevens JM, Rossor MN. Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation: A clinicopathological study. Brain. 2000 May;123 ( Pt 5):894-907.</citation>
    <PMID>10775535</PMID>
  </reference>
  <reference>
    <citation>Cabrejo L, Guyant-Maréchal L, Laquerrière A, Vercelletto M, De la Fournière F, Thomas-Antérion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D. Phenotype associated with APP duplication in five families. Brain. 2006 Nov;129(Pt 11):2966-76. Epub 2006 Sep 7.</citation>
    <PMID>16959815</PMID>
  </reference>
  <reference>
    <citation>Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012 Mar;69(3):368-72. doi: 10.1001/archneurol.2011.830.</citation>
    <PMID>22410444</PMID>
  </reference>
  <reference>
    <citation>Mendez MF, Catanzaro P, Doss RC, ARguello R, Frey WH 2nd. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994 Oct-Dec;7(4):230-3.</citation>
    <PMID>7826492</PMID>
  </reference>
  <reference>
    <citation>Risse SC, Lampe TH, Bird TD, Nochlin D, Sumi SM, Keenan T, Cubberley L, Peskind E, Raskind MA. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis Assoc Disord. 1990 Winter;4(4):217-25.</citation>
    <PMID>2264979</PMID>
  </reference>
  <reference>
    <citation>Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G, Hegde M, Cornes SB, Henry ML, Nelson AB, Seeley WW, Geschwind MD, Gorno-Tempini ML, Shih T, Kirsch HE, Garcia PA, Miller BL, Mucke L. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013 Sep 1;70(9):1158-66. doi: 10.1001/jamaneurol.2013.136.</citation>
    <PMID>23835471</PMID>
  </reference>
  <reference>
    <citation>Vossel KA, Ranasinghe KG, Beagle AJ, Mizuiri D, Honma SM, Dowling AF, Darwish SM, Van Berlo V, Barnes DE, Mantle M, Karydas AM, Coppola G, Roberson ED, Miller BL, Garcia PA, Kirsch HE, Mucke L, Nagarajan SS. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol. 2016 Dec;80(6):858-870. doi: 10.1002/ana.24794. Epub 2016 Nov 7.</citation>
    <PMID>27696483</PMID>
  </reference>
  <reference>
    <citation>Förstl H, Burns A, Levy R, Cairns N, Luthert P, Lantos P. Neurologic signs in Alzheimer's disease. Results of a prospective clinical and neuropathologic study. Arch Neurol. 1992 Oct;49(10):1038-42.</citation>
    <PMID>1417511</PMID>
  </reference>
  <reference>
    <citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007 Sep 6;55(5):697-711.</citation>
    <PMID>17785178</PMID>
  </reference>
  <reference>
    <citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):E2895-903. doi: 10.1073/pnas.1121081109. Epub 2012 Aug 6.</citation>
    <PMID>22869752</PMID>
  </reference>
  <reference>
    <citation>Kleen JK, Scott RC, Holmes GL, Roberts DW, Rundle MM, Testorf M, Lenck-Santini PP, Jobst BC. Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology. 2013 Jul 2;81(1):18-24. doi: 10.1212/WNL.0b013e318297ee50. Epub 2013 May 17.</citation>
    <PMID>23685931</PMID>
  </reference>
  <reference>
    <citation>McAreavey MJ, Ballinger BR, Fenton GW. Epileptic seizures in elderly patients with dementia. Epilepsia. 1992 Jul-Aug;33(4):657-60.</citation>
    <PMID>1628580</PMID>
  </reference>
  <reference>
    <citation>Heyman A, Wilkinson WE, Hurwitz BJ, Helms MJ, Haynes CS, Utley CM, Gwyther LP. Early-onset Alzheimer's disease: clinical predictors of institutionalization and death. Neurology. 1987 Jun;37(6):980-4.</citation>
    <PMID>3587649</PMID>
  </reference>
  <reference>
    <citation>Oh H, Jagust WJ. Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. J Neurosci. 2013 Nov 20;33(47):18425-37. doi: 10.1523/JNEUROSCI.2775-13.2013.</citation>
    <PMID>24259567</PMID>
  </reference>
  <reference>
    <citation>Huijbers W, Mormino EC, Schultz AP, Wigman S, Ward AM, Larvie M, Amariglio RE, Marshall GA, Rentz DM, Johnson KA, Sperling RA. Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain. 2015 Apr;138(Pt 4):1023-35. doi: 10.1093/brain/awv007. Epub 2015 Feb 11.</citation>
    <PMID>25678559</PMID>
  </reference>
  <reference>
    <citation>Scharfman HE. Alzheimer's disease and epilepsy: insight from animal models. Future Neurol. 2012 Mar 1;7(2):177-192.</citation>
    <PMID>22723738</PMID>
  </reference>
  <reference>
    <citation>Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C; Medical Research Council Cognitive Function and Ageing Study. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009 Mar;194(3):212-9. doi: 10.1192/bjp.bp.108.049619.</citation>
    <PMID>19252147</PMID>
  </reference>
  <reference>
    <citation>Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012 Nov 21;308(19):2020-9. doi: 10.1001/jama.2012.36918.</citation>
    <PMID>23168825</PMID>
  </reference>
  <reference>
    <citation>Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996 Jan;46(1):130-5.</citation>
    <PMID>8559361</PMID>
  </reference>
  <reference>
    <citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000 May;157(5):708-14.</citation>
    <PMID>10784462</PMID>
  </reference>
  <reference>
    <citation>Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002 Sep 25;288(12):1475-83.</citation>
    <PMID>12243634</PMID>
  </reference>
  <reference>
    <citation>Sink KM, Covinsky KE, Newcomer R, Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J Am Geriatr Soc. 2004 Aug;52(8):1277-83.</citation>
    <PMID>15271114</PMID>
  </reference>
  <reference>
    <citation>Peters KR, Rockwood K, Black SE, Bouchard R, Gauthier S, Hogan D, Kertesz A, Loy-English I, Beattie BL, Sadovnick AD, Feldman HH. Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology. 2006 Feb 28;66(4):523-8.</citation>
    <PMID>16505306</PMID>
  </reference>
  <reference>
    <citation>Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain. 2005 Nov;128(Pt 11):2612-25. Epub 2005 Sep 29.</citation>
    <PMID>16195246</PMID>
  </reference>
  <reference>
    <citation>Gallagher-Thompson D, Brooks JO 3rd, Bliwise D, Leader J, Yesavage JA. The relations among caregiver stress, &quot;sundowning&quot; symptoms, and cognitive decline in Alzheimer's disease. J Am Geriatr Soc. 1992 Aug;40(8):807-10.</citation>
    <PMID>1634724</PMID>
  </reference>
  <reference>
    <citation>Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B, Devanand D, Honig L, Stern Y. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007 Dec;64(12):1755-61.</citation>
    <PMID>18071039</PMID>
  </reference>
  <reference>
    <citation>O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol. 1992 Jan-Mar;5(1):45-52.</citation>
    <PMID>1571074</PMID>
  </reference>
  <reference>
    <citation>Morriss RK, Rovner BW, Folstein MF, German PS. Delusions in newly admitted residents of nursing homes. Am J Psychiatry. 1990 Mar;147(3):299-302.</citation>
    <PMID>2309945</PMID>
  </reference>
  <reference>
    <citation>Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadimitriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005 Oct;62(10):1601-8.</citation>
    <PMID>16216946</PMID>
  </reference>
  <reference>
    <citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.</citation>
    <PMID>21514250</PMID>
  </reference>
  <reference>
    <citation>Ponomareva NV, Korovaitseva GI, Rogaev EI. EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease. Neurobiol Aging. 2008 Jun;29(6):819-27. Epub 2007 Feb 12.</citation>
    <PMID>17293007</PMID>
  </reference>
  <reference>
    <citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Rohrer JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenberghe R, Rascovsky K, Patterson K, Miller BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M. Classification of primary progressive aphasia and its variants. Neurology. 2011 Mar 15;76(11):1006-14. doi: 10.1212/WNL.0b013e31821103e6. Epub 2011 Feb 16.</citation>
    <PMID>21325651</PMID>
  </reference>
  <reference>
    <citation>Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14(1):33-40.</citation>
    <PMID>12053130</PMID>
  </reference>
  <reference>
    <citation>Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). J Prev Alzheimers Dis. 2015 Dec 1;2(4):227-241.</citation>
    <PMID>27019841</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuro-psychiatric symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

